BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9815763)

  • 1. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
    Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
    Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
    Myers DE; Jun X; Clementson D; Donelson R; Sicheneder A; Hoffman N; Bell K; Sarquis M; Langlie MC; Turner N; Uckun FM
    Leuk Lymphoma; 1997 Oct; 27(3-4):275-302. PubMed ID: 9402326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
    Flavell DJ; Warnes S; Noss A; Flavell SU
    Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
    Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.
    Uckun FM; Chelstrom LM; Tuel-Ahlgren L; Dibirdik I; Irvin JD; Langlie MC; Myers DE
    Antimicrob Agents Chemother; 1998 Feb; 42(2):383-8. PubMed ID: 9527790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
    Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
    Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
    Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
    Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R; Chelstrom LM; Wendorf HR; Schneider EA; Covalciuc K; Johnson B; Clementson D; Irvin JD; Myers DE; Uckun FM
    Leuk Lymphoma; 1996 Jun; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
    Ramakrishnan S; Houston LL
    Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
    Messinger Y; Reaman GH; Ek O; Uckun FM
    Leuk Lymphoma; 1999 Apr; 33(3-4):289-93. PubMed ID: 10221508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma.
    Ek O; Waurzyniak B; Myers DE; Uckun FM
    Clin Cancer Res; 1998 Jul; 4(7):1641-7. PubMed ID: 9676838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.